Investigating the effect of letrozole on AUB

To investigate the effect of letrozole on AUB and compare it with progesterone in patients with endometrial proliferative pathology or endometrial hyperplasia.

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250404065200N1

Enrollment

132

Registered

2025-10-25

Start date

2025-08-23

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abnormal uterine bleeding. Abnormal uterine and vaginal bleeding,unspecified

Interventions

Intervention 1: Intervention group: 66 people who received 5 mg of letrozole tablets daily. Intervention 2: Control group: 66 people receiving 10 mg of medroxyprogesterone tablets daily.

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Premenopausal women who complain of abnormal vaginal bleeding

Exclusion criteria

Exclusion criteria: Pregnant and breastfeeding women Menopausal women Known sensitivity or intolerance to the medications used

Design outcomes

Primary

Measure	Time frame
Endometrial pathology, which can be simple hyperplasia or proliferative endometrium. Timepoint: Three months after therapeutic intervention. Method of measurement: Repeat biopsy and normalization of endometrial pathology.;Measuring endometrial thickness. Timepoint: Three months after therapeutic intervention. Method of measurement: Repeat ultrasound and check for reduced endometrial thickness.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAfsoon Khani

Iran University of Medical Sciences

dr.afsoonkhani@gmail.com+98 21 86701

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026